Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Director departure
Quarterly results
|
|
IMMUNE PHARMACEUTICALS INC (IMNPQ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2016 |
8-K
| Form 8-K - Current report |
| 03/31/2016 |
8-K
| Quarterly results |
| 08/14/2014 |
8-K
| Quarterly results|
Docs:
|
"Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Aug. 14, 2014– Immune Pharmaceuticals Inc. , announced today its operating results for the quarter ended June 30, 2014. Dr. Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals, Inc., stated: “Following the completion of a $10.2 million capital raise in March 2014, in the second quarter, we have been able to advance the preparation of Phase II clinical trials for Bertilimumab. As a result, both trials, in Bullous Pemphigoid, an Orphan Auto-Immune Disease of the skin, and in Ulcerative Colitis trial, are initiating patient screening in the third quarter.” Highlights for the Quarter ended ..." |
|
| 08/15/2011 |
8-K
| Form 8-K - Current report |
| 05/10/2011 |
8-K
| Form 8-K - Current report |
| 02/25/2010 |
8-K
| Form 8-K - Current report |
| 11/10/2009 |
8-K
| Form 8-K - Current report |
|
|